Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation

New England Journal of Medicine

Volumn 376, Issue 17, 2017, Pages 1627-1636

  Calkins, Hugh ^a   Willems, Stephan ^b   Gerstenfeld, Edward P ^e   Verma, Atul ^f   Schilling, Richard ^g   Hohnloser, Stefan H ^c   Okumura, Ken ⁱ   Serota, Harvey ^j   Nordaby, Matias ^d   Guiver, Kelly ^h   Biss, Branislav ^k   Brouwer, Marc A ^l   Grimaldi, Massimo ^m  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY HEART CENTER HAMBURG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^h BOEHRINGER INGELHEIM LTD   (United Kingdom)

ⁱ SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^j St John's Heart and Vascular Center   (United States)

^k BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^l RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^m MIULLI GENERAL HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CATHETER ABLATION; CONTROLLED STUDY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; GROIN HEMATOMA; HEART TAMPONADE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; HEMORRHAGE; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; STROKE; WARFARIN;

EID: 85017388458     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1701005     Document Type: Article

References (35)

1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962.
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64(21): E1-e76.
3. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for patient selection, procedural techniques, patient management and followup, definitions, endpoints, research trial design. Europace 2012; 14: 528-606.
4. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014; 129: 2638-44.
5. Page SP, Siddiqui MS, Finlay M, et al. Catheter ablation for atrial fibrillation on uninterrupted warfarin: Can it be done without echo guidance J Cardiovasc Electrophysiol 2011; 22: 265-70.
6. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2012; 59: 1168-74.
7. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2013; 10: 483-9.
8. Yamaji H, Murakami T, Hina K, et al. Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clin Drug Investig 2013; 33: 409-18.
9. Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR. Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. J Interv Card Electrophysiol 2013; 37: 241-7.
10. Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol 2013; 6: 460-6.
11. Nin T, Sairaku A, Yoshida Y, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol 2013; 36: 172-9.
12. Stepanyan G, Badhwar N, Lee RJ, et al. Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation. J Interv Card Electrophysiol 2014; 40: 33-8.
13. Arshad A, Johnson CK, Mittal S, et al. Comparative safety of periablation anticoagulation strategies for atrial fibrillation: Data from a large multicenter study. Pacing Clin Electrophysiol 2014; 37: 665-73.
14. Armbruster HL, Lindsley JP, Moranville MP, et al. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. Ann Pharmacother 2015; 49: 278-84.
15. Nagao T, Inden Y, Shimano M, et al. Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. Intern Med 2015; 54: 1167-73.
16. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2014; 63: 982-8.
17. Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. J Cardiovasc Electrophysiol 2013; 24: 861-5.
18. Zhao Y, Yang Y, Tang X, Yu X, Zhang L, Xiao H. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J Interv Card Electrophysiol 2017 January 12 (Epub ahead of print).
19. Wu S, Yang YM, Zhu J, et al. Metaanalysis of efficacy and safety of new oral anticoagulants compared with uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2016; 117: 926-34.
20. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation. Europace 2013; 15: 625-51.
21. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015; 36: 1805-11.
22. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
23. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.
24. Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB. Dabigatran versus warfarin for atrial fibrillation in realworld clinical practice: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2016; 9: 126-34.
25. Larsen TB, Rasmussen LH, Skjh F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-73.
26. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016; 176: 1662-71.
27. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015; 131: 157-64.
28. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-4.
29. ICH harmonised tripartite guideline. Guideline for Good Clinical Practice E6(R1) (http://www. ich. org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline. pdf ).
30. Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
31. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J Thromb Haemost 2005; 3: 692-4.
32. Sardar P, Nairooz R, Chatterjee S, Wetterslev J, Ghosh J, Aronow WS. Metaanalysis of risk of stroke or transient ischemic attack with dabigatran for atrial fibrillation ablation. Am J Cardiol 2014; 113: 1173-7.
33. Aryal MR, Ukaigwe A, Pandit A, et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014; 114: 577-82.
34. Larsen TB, Skjh F, Nielsen PB, Kjdgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ 2016; 353: I3189.
35. Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 2016; 5(6): E003725.